Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Alameda-based Scribe Therapeutics has filed for a $75 million Nasdaq IPO, signaling a new test for investor interest in earlier-stage gene-editing firms.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Scribe Therapeutics is moving toward a public offering on the Nasdaq exchange. The company focuses on gene-editing technologies targeting cardiovascular diseases and cholesterol management.
Coverage from Renaissance Capital, The Business Journals, Investing.com, Moomoo, and Endpoints News highlights the firm's Alameda base and its connection to major industry stockholders, including Eli Lilly. Analysts emphasize the filing as a bellwether for market appetite regarding biotech companies in the earlier stages of development.
Remaining coverage details such as the official stock ticker, anticipated launch date, or specific clinical trial timelines have not yet been specified.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the primary business of Scribe Therapeutics?
The company is a biotech firm focused on gene-editing technology for cardiovascular diseases and cholesterol management.
Where is the company located?
Scribe Therapeutics is based in Alameda.
Who are some of the notable stockholders mentioned?
Stockholders include Eli Lilly.
Coverage (5)
- SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO renaissancecapital.com · 1d ago
- Meet the gene-editing, cholesterol-fighting Alameda company looking for IPO riches The Business Journals · 1d ago
- Scribe Therapeutics files for proposed Nasdaq IPO By Investing.com Investing.com South Africa · 1d ago
- Scribe Therapeutics Stockholders Include Eli Lilly Moomoo · 1d ago
- Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs Endpoints News · 1d ago
Topics
Related trends
Korea Said to Prepare for Currency Flow From SK Hynix US Listing
SK Hynix moves toward a Nasdaq ADR listing and share issue, prompting preparations for potential currency shifts in Korea.
Quantum Computing Stocks: Europe's IQM To Debut On Nasdaq
European quantum computing firm IQM has completed its Nasdaq debut following a business combination with RAAQ.
Sandwich chain Jersey Mike's files for IPO, reports 50% same-store sales growth in recent years
Blackstone-backed sandwich chain Jersey Mike’s has officially filed for an IPO, targeting a listing on the New York Stock Exchange.
Dow rises more than 300 points to record, Nasdaq falls again as chipmakers struggle: Live updates
U.S. markets show mixed signals as the Dow reaches a record high while tech shares face pressure amid shifting labor market expectations.
Lime begins life as a public company after years of uncertainty
Lime has officially entered the public market, raising $167 million in its initial public offering as shares began trading today.
Italy's Bending Spoons, owner of AOL and Vimeo, valued at $20 billion in US market debut
Bending Spoons, the parent company of AOL and Vimeo, has entered the US stock market with a $20 billion valuation.